Press Releases
October 24, 2023
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
October 19, 2023
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting
October 18, 2023
NexImmune Announces 1-for-25 Reverse Stock Split
August 31, 2023
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy
August 10, 2023
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates
June 5, 2023
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
May 22, 2023
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting
May 15, 2023
NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates
April 26, 2023
NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting
March 28, 2023
NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Displaying 1 - 10 of 71